Personalized Immunotherapy: Adoptive Cell (TIL) Transfer

  My previous column from January 2016, “Personalized Immunotherapy: Therapeutic Cancer Vaccines” was Part 1 of a 2-Part series on “personalized” immunotherapies that are currently in clinical trials. As a recap, this is an entirely new model of drug therapy! Instead of standardized identical batches…

Read Full Post

FDA Grants Breakthrough Designation for Pembrolizumab

Expedited FDA Review for CRC Drug This post was compiled and reviewed by Anjee Davis, Andi Dwyer, Nancy Roach and Dr. Tom Marsilje This week the Food and Drug Administration (FDA) granted “Breakthrough Therapy Designation” to Merck’s Keytruda® (pembrolizumab) for patients with MSI-high colorectal cancer….

Read Full Post

Lisa Fund Grant: Now Accepting Applications

Postdoctoral or clinical research fellows planning to do translational or clinical research that focuses on novel THERAPEUTIC APPROACHES for late-stage metastatic colorectal cancer may now apply for The Fight Colorectal Cancer-AACR research grant. This grant is distributed through Fight Colorectal Cancer’s Lisa Fund. Our Lisa Fund was designed…

Read Full Post

FDA Approves Avastin for New Second-Line Use

For patients with metastatic colorectal cancer, the Food and Drug Administration (FDA) has approved a new use of Avastin® (bevacizumab): It can be continued as part of ‘second-line’ combination therapy, even if it was used in first-line therapy. When stage IV cancer progresses despite use…

Read Full Post

New Cancer Drug Zaltrap Discounted by 50%

By Curt Pesman and Mary Miller In an unusual move, sanofi pharmaceutical company has instituted a 50 percent discount, effective immediately, on its latest cancer drug Zaltrap.  The reason for the sharp price drop, company officials said, was “market resistance” to the initial price. Zaltrap was…

Read Full Post

Memorial Sloan-Kettering Will Not Offer Zaltrap

Memorial Sloan-Kettering Cancer Center made a very public announcement—and explanation—today in a New York Times op-ed about why they will not offer the new drug Zaltrap® (ziv-aflibercept) to its metastatic colorectal cancer patients. The authors, all world-renowned cancer specialists at the world’s oldest cancer center, in…

Read Full Post

FDA Approves Regorafenib for Metastatic CRC

  The FDA today approved the use of the drug regorafenib (brand name Stivarga) for patients whose metastatic colorectal cancer has progressed despite all currently approved treatment regimens. This is the second new drug approved by the FDA recently after a drought of 5 years in…

Read Full Post

Ziv-Aflibercept gets FDA approval

Ziv-Aflibercept Approved as 2nd line treatment for metastatic CRC   For the first time in more than five years, the FDA has approved a new drug for certain patients who have metastatic colorectal cancer. The FDA has approved ZALTRAP® (ziv-aflibercept) to be used with FOLFIRI as…

Read Full Post
Page 1 of 3123